Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Multiple Myeloma

Rare Cancers

Multiple Myeloma Clinical Trials and Treatments

Also called Myeloma, Plasma Cell Myeloma, Kahler Disease, Relapsed Refractory Multiple Myeloma, Smoldering Myeloma

Plasma cells live in the bone marrow and make the antibodies that fight infection. In multiple myeloma, one plasma cell turns cancerous and copies itself until the marrow fills with identical myeloma cells. Those cells do 3 kinds of damage. They crowd out the marrow's normal work, so red cells, white cells and platelets fall, which explains the tiredness, infections and bruising.

In plain words, multiple myeloma is a cancer of plasma cells, the white blood cells that make antibodies. The abnormal cells crowd the bone marrow, weaken bones, and release a protein that can harm the kidneys.

Get an email when new Multiple Myeloma trials open or the FDA decides. Get alerts

Multiple Myeloma

Where treatments stand, from ClinicalTrials.gov and FDA labels

FDA review2

Anito-cel, Dec 23, 2026 · Mezigdomide, May 13, 2027

FDA-approved medicines28

Abecma · Blenrep · Carvykti · Darzalex · Elrexfio · 23 more

Multiple Myeloma has 28 FDA-approved medicines, 706 open or active clinical trials, and a pending FDA decision on Anito-cel, due Dec 23, 2026.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Latest for Multiple Myeloma

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Multiple Myeloma

They eat into bone, which causes pain, fractures and a dangerous rise in blood calcium. They also pour out a single useless antibody fragment, called M protein, that thickens the blood and clogs the kidneys. The disease is called multiple myeloma because it usually shows up in many bones at once.

Keep reading about Multiple Myeloma

Doctors stage it with 2 blood tests, beta-2-microglobulin and albumin, plus genetic changes in the myeloma cells. Myeloma that has not yet caused symptoms is called smoldering myeloma and is often watched rather than treated. Myeloma that comes back after treatment is called relapsed, and myeloma that keeps growing during treatment is called refractory. Most trials describe their patients using those 2 words and the number of prior treatments.

Myeloma sits at the edge of the definition used for rare diseases in the United States. The National Cancer Institute estimated 202,793 people were living with it in 2023. Death rates have been falling about 3% a year, and the 5-year relative survival is now 63.7%, because the number of treatment options has grown so quickly.

What are the symptoms of Multiple Myeloma?

These are common symptoms of Multiple Myeloma, and how strong they are varies from person to person.

  • Bone pain, most often in the back or ribs
  • Bones that break easily
  • Frequent infections or a fever with no clear cause
  • Tiredness and shortness of breath from low red blood cells
  • Easy bruising or bleeding
  • Weakness in the arms or legs

Who gets Multiple Myeloma?

Myeloma is a disease of older adults. The median age at diagnosis is 69, and about a third of cases are found between ages 65 and 74. Men are diagnosed more often than women (9.1 versus 6.1 per 100,000 a year), and Black Americans are diagnosed at 2 to 2.5 times the rate of white Americans. A silent precursor stage called MGUS, in which the abnormal protein shows up on a blood test but causes no harm, is a recognized risk factor. Radiation and certain chemical exposures also raise risk.

Next steps: find trials you might fitcompare treatmentsget help payingget alerts

Which medicines are FDA-approved for Multiple Myeloma?

There are currently 28 FDA-approved medications for Multiple Myeloma.

idecabtagene vicleucel
Bristol Myers Squibb (Celgene Corporation); developed with 2seventy bio
Search
belantamab mafodotin-blmf
GSK (GlaxoSmithKline)
Search
ciltacabtagene autoleucel
Janssen Biotech (Johnson & Johnson); co-marketed with Legend Biotech
Search
daratumumab
Janssen Biotech (Johnson & Johnson)
Search
elranatamab-bcmm
Pfizer
Search
elotuzumab
Bristol Myers Squibb
Search
carfilzomib
Amgen (Onyx Pharmaceuticals, an Amgen subsidiary)
Search
linvoseltamab-gcpt
Regeneron Pharmaceuticals
Search
ixazomib
Takeda (Millennium Pharmaceuticals)
Search
pomalidomide
Bristol Myers Squibb (Celgene Corporation); generic pomalidomide is made by several companies
Search
lenalidomide
Bristol Myers Squibb (Celgene Corporation); generic lenalidomide is made by several companies
Search
isatuximab-irfc
Sanofi (sanofi-aventis U.S. LLC)
Search
talquetamab-tgvs
Janssen Biotech (Johnson & Johnson)
Search
teclistamab-cqyv
Janssen Biotech (Johnson & Johnson)
Search
thalidomide
Bristol Myers Squibb (Thalomid is a trademark of Celgene Corporation, a Bristol Myers Squibb company)
Search
bortezomib
Takeda (Millennium Pharmaceuticals); generic bortezomib is made by several companies
Search
selinexor
Karyopharm Therapeutics
Search
iberdomide
Bristol Myers Squibb (Celgene Corporation, a Bristol Myers Squibb company)
Search
Aphexda
motixafortide
Gamida Cell Inc.
Search
Bilprevda
denosumab
Organon LLC
Search
Carmustine
carmustine
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
Search
Corticosteroids
dexamethasone
Doxil
doxorubicin hydrochloride
Baxter Healthcare Corporation
Search
Frindovyx
cyclophosphamide
AVYXA Pharma, LLC
Search
Melphalan
melphalan hydrochloride
Fresenius Kabi USA, LLC
Search
Mozobil
plerixafor
Sanofi-Aventis U.S. LLC
Search
Pamidronate Disodium
pamidronate disodium
Hospira, Inc.
Search
zoledronic acid
zoledronic acid
Gland Pharma Limited
Search

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

Which new Multiple Myeloma medicines are in trials?

Investigational medicines Trial Friend tracks for Multiple Myeloma, with trial results, safety findings and where each one stands.

How to get help paying for Multiple Myeloma treatment

Charity funds and drugmaker programs for Multiple Myeloma, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds
  • From a charity · HealthWell Foundation
    Multiple Myeloma (Medicare Access) fund
    Open

    Pays for: Copays, premiums or other treatment costs. Medicare patients only.

Status as each foundation showed it on November 9, 2026.
Drugmaker programs
Open a medicine for who qualifies, by insurance type.

Every program and fund for Multiple Myeloma, by insurance →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Multiple Myeloma

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Multiple Myeloma resources

Reputable organizations and medical references for learning more about Multiple Myeloma, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Multiple Myeloma

Use this Multiple Myeloma clinical trial finder to see the 10 studies recruiting patients in the United States and worldwide, with eligibility criteria in plain English. All of them test a treatment. Every trial comes from ClinicalTrials.gov.

FDA decision ahead: Anito-cel (anitocabtagene autoleucel), due December 23, 2026; Mezigdomide, due May 13, 2027. All upcoming decisions

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

706 active trials worldwide
Filter:
Sort:
RecruitingTreatment trialPhase 3Recently updatedNCT07772024

Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma

Intervention: InoPd, Investigator's choice of SAT

Sponsor: CellCentric Ltd.

The main purpose of this study is to find out whether inobrodib, when given with pomalidomide and dexamethasone, works better than standard treatment for people whose multiple myeloma has come back or has not improved after previous treatment. The study will look at how long peop...

Ages 18 Years+
Started Nov 2026Updated yesterdayEst. Nov 2029 (~3 years)
RecruitingTreatment trialPhase 2Recently updatedNCT06948084

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

Intervention: Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, FDG-Positron Emission Tomography, Pomalidomide, Teclistamab

Sponsor: National Cancer Institute (NCI)

This phase II trial compares the effect of the combination of daratumumab-hyaluronidase (daratumumab) and teclistamab to the usual treatment of daratumumab, pomalidomide, dexamethasone or daratumumab, carfilzomib and dexamethasone in treating patients with multiple myeloma that h...

Ages 18 Years+
Expected to start May 2027Updated yesterdayEst. Feb 2028 (~1y 3m)
RecruitingTreatment trialPhase 3Recently updatedNCT06615479

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Intervention: BMS-986393, Cyclophosphamide, Fludarabine, Daratumumab, Pomalidomide, Dexamethasone, Carfilzomib

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Celgene Corporation

The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.

Ages 18 Years+
Started Mar 2025Updated yesterdayEst. Dec 2027 (~1y 1m)
RecruitingTreatment trialPhase 1/2Recently updatedNCT05714839

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

Intervention: Belantamab, Belantamab mafodotin, Pomalidomide, Dexamethasone

Sponsor: GlaxoSmithKline

The study consists of three parts:

Ages 18 Years+
Started Jun 2023Updated 2 days agoEst. Aug 2028 (~1y 8m)
RecruitingTreatment trialPhase 3Recently updatedNCT03823534

Post-Op Pain Control for Prophylactic Intramedullary Nailing.

Intervention: Ketorolac, Normal saline, Acetaminophen, Oxycodone Acetaminophen, Morphine, Hydrocodone/Acetaminophen, Oxycodone

Sponsor: St. Louis University

Nationally, the opioid crisis has become a major epidemic with increasing mortality rates each year. Orthopedic surgeons routinely prescribe narcotics instead of NSAIDs for post-op pain control because of risk of delayed healing and nonunion due to NSAID use. Orthopedic oncology,...

Ages 18 Years+1 location
Started Feb 2019Updated 2 days agoEst. Mar 2027 (~4 months)
Find Multiple Myeloma trials near you, ranked by distance →
Active trial locations86 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+78 more

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Phase 1
Phase 2
Phase 3
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Multiple Myeloma trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Multiple Myeloma foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Multiple Myeloma patient communities

Facebook groups, Reddit communities and YouTube channels where Multiple Myeloma patients, caregivers and advocacy groups talk.

Multiple Myeloma news and guides

Trial Friend articles about Multiple Myeloma, newest first

Companies developing Multiple Myeloma treatments

Drugmakers that list Multiple Myeloma in their rare disease portfolio, with makers of its treatments first.

Questions people ask about Multiple Myeloma